<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>244-GANCICLOVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="GANCICLOVIR" rxcui="4678">
<ATC code="S01AD09" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DIDANOSINE" rxcui="3364">
<ATC code="J05AF02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects of the didanosine, and especially the mitochondrial toxicity, due to substantial increase of its concentrations. In addition, risk of decrease of the effectiveness of the ganciclovir due to decrease of its concentrations, if the two medications are ingested in an interval of less than 2 hours</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>244-GANCICLOVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="GANCICLOVIR" rxcui="4678">
<ATC code="S01AD09" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ZALCITABINE" rxcui="3363">
<ATC code="J05AF03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of onset of peripheral neuropathy due to addition of undesirable effects</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Regular clinical and biological monitoring, especially at the beginning of the administration of the two medications together. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>244-GANCICLOVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="GANCICLOVIR" rxcui="4678">
<ATC code="S01AD09" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ZIDOVUDINE " rxcui="11413">
<ATC code="J05AR05" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the hematological toxicity (addition of effects of bone marrow toxicity)</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Stop the zidovudine temporarily; CBC, and, reintroduce, if possible, the zidovudine in small doses. </COMMENT>
</INTERACTION>
</INTERACTIONS>
